Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Korea, republic of
  4. Korea Stock Exchange
  5. Celltrion, Inc.
  6. News
  7. Summary
    A068270   KR7068270008

CELLTRION, INC.

(A068270)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Celltrion Rallies After Positive Data on Covid-19 Treatment

06/14/2021 | 12:43am EDT

By Kwanwoo Jun

Celltrion Inc.'s shares rallied Monday after the company released positive top-line clinical trial data on its Covid-19 treatment candidate, known as Regkirona in the industry.

Shares of the South Korean biotech company jumped as much as 6.0% to 281,500 won before paring gains to trade 5.7% higher at KRW280,500. It outperformed the benchmark Kospi's 0.1% gain.

Celltrion said its Phase 3 global clinical trial, which involved 1,315 participants in 13 countries, found that Regkirona is a safe and effective treatment candidate.

Regkirona eased severe Covid-19 symptoms in more than 70% of those patients and reduced their recovery period by up to 4.9 days during the latest clinical trial, Celltrion said.

The company said it is seeking approval for Regkirona in the U.S. and Europe. It is trying to list Regkirona as an authorized item in South Korea, after authorities granted it conditional approval earlier this year.

Write to Kwanwoo Jun at kwanwoo.jun@wsj.com

(END) Dow Jones Newswires

06-14-21 0243ET

All news about CELLTRION, INC.
10/11EU assesses Regeneron/Roche COVID-19 antibody cocktail for authorisation
RE
10/06U.S. to invest another $1 bln in rapid COVID-19 tests
RE
09/23Celltrion Awards Up to $626 Million from the Department of Defense to Supply Covid-19 P..
CI
09/21EU signs joint procurement deal for Eli Lilly COVID-19 treatment
RE
09/20180 LIFE SCIENCES : Plans Supply Deal With Celltrion Healthcare For Anti-TNF Product Trial..
MT
09/17South Korea approves Celltrion's COVID-19 treatment for use
RE
08/13MARKET CHATTER : Brazil Approves Celltrion's COVID-19 Treatment for Emergency Use
MT
08/06MARKET CHATTER : Celltrion, TriLink BioTechnologies Enter Deal to Develop mRNA Vaccine Pla..
MT
08/02MARKET CHATTER : Celltrion Healthcare Secures Orders for Anticancer Biosimilars from Brazi..
MT
07/22Inhalon Biopharma, Inc. Collaborates with Celltrion, Inc. to Develop Nebulized Form of ..
CI
More news
Analyst Recommendations on CELLTRION, INC.
More recommendations
Financials
Sales 2021 1 986 B 1,68 B 1,68 B
Net income 2021 619 B 0,52 B 0,52 B
Net cash 2021 236 B 0,20 B 0,20 B
P/E ratio 2021 48,2x
Yield 2021 0,01%
Capitalization 30 055 B 25 414 M 25 426 M
EV / Sales 2021 15,0x
EV / Sales 2022 12,1x
Nbr of Employees 2 034
Free-Float 76,0%
Chart CELLTRION, INC.
Duration : Period :
Celltrion, Inc. Technical Analysis Chart | A068270 | KR7068270008 | MarketScreener
Technical analysis trends CELLTRION, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Last Close Price 220 000,00 KRW
Average target price 317 071,43 KRW
Spread / Average Target 44,1%
EPS Revisions
Managers and Directors
Wu-Sung Ki Chief Executive Officer & Director
Ho-Seop Lee Finance Director
Jung-Jin Seo Chairman
Sung-Han Lee Head-Legal & Compliance Support
Dong-Il Kim Independent Director
Sector and Competitors
1st jan.Capi. (M$)
CELLTRION, INC.-38.72%25 414
MODERNA, INC.210.34%130 866
LONZA GROUP AG26.90%58 060
IQVIA HOLDINGS INC.38.89%47 683
SEAGEN INC.-1.38%31 426
ALNYLAM PHARMACEUTICALS, INC.60.47%24 787